Non-compaction of the Left Ventricular Myocardium, reverse cardiac remodeling and PulseCath left ventricular assist device
Abstract
The diagnostics of the left ventricular non-compaction, prognosis assessment for this pathological
condition, the relationship with other better-known cardiomyopathies are the most complicated
and relevant problems of the modern cardiology.
The article gives an example of the extremely rare combination of the five structural and functional
myocardial pathologies in a 39-year-old patient which had led to severe and steadily progressive
heart failure: hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compaction, atrial septal defect and morphologically confirmed mitral valve dysplasia. The patient
underwent an organ-sparing surgery (reverse cardiac remodeling) combined with the PulseCath iVAC 2L left ventricular assist device (Netherlands) implantation in the early postoperative
period. Particular attention is drawn to the importance of etiological diagnosis for decisions
on personalized treatment, the volume and surgical techniques. In the discussion the authors
analyze the pathogenesis of progression and the possible genetic relationship between the three
different and most common noncoronary cardiomyopathies.
Keywords:hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compaction, valvular dysplasia, reverse cardiac remodeling, extracorporeal artificial ventricle
Clin. Experiment. Surg. Petrovsky J. 2017; 5 (1): 15–21.
DOI: 10.24411/2308-1198-2017-00015
Received: 21.01.2017. Accepted: 07.02.2017.
References
1. Blagova O.V., A.V. Nedostup Dilated cardiomyopathy syndrome: nosological diagnosis as the bases of differential treatment. Clin Experiment Surg Petrovsky J. 2014; (1): 29–41.
(in Russian)
2. Yancy С.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA
Guideline for the Management of Heart Failure: Executive Summary. A Report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines.
Circulation. 2013; 128: 1810–52. doi: https://doi.org/10.1161/
CIR.0b013e31829e8807.
3. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure: The Task Force for the diagnosis and treatment of acute and
chronic heart failure of the European Society of Cardiology (ESC).
Developed with the special contribution of the Heart Failure Associa-
tion (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129–200.
4. Towbin J.A., Lorts A., Jefferies J.L. Left ventricular non-compaction cardiomyopathy. Lancet. 2015; 386: 813–25.
5. Oechslin E., Attenhofer Jost C.H., Rojas J.R., et al. Longterm
followup of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Сoll Cardiol.
2000; 36: 493–500.
6. Polyak M.E., E.A. Merschina, E.V. Zaklyasminskaya. Left ventricular noncompaction: symptom, syndrome or variant of the devel-
opment? Russ J Cardiol. 2017; (2). (in Russian)
7. Dzemeshkevich S.L, Frolova Yu.V., Fedorov D.N. Mitral valve
dysplasia as a component of dilated cardiomyopathy. Clin Experiment Surg Petrovsky J. 2015; (2): 18–24. (in Russian)
8. Dzemeshkevich S.L., Stephenson L.W. Myocardiac dysfunction and cardiac surgery. Moscow: GEOTARMedia, 2009: 31–70.
(in Russian)
9. Luk A., Metawee M., Ahn E., et al. Do clinical diagnoses correlate with pathological diagnoses in cardiac transplant patients?
The importance of endomyocardial biopsy. Can J Cardiol. 2009;
Vol. 25 (N 2): e48–е54.
10. Sato A., Sakamoto N., Ando K., et al. Dilated Phase of Hypertrophic Cardiomyopathy Caused by Two Different Sarcomere Mutations, Treated with Surgical Left Ventricular Reconstruction and
Cardiac Resynchronization Therapy with a Defibrillator. Intern Med.
2012; Vol. 51: 2559–64. doi: 10.2169/internalmedicine.51.7684.
11. Nonaka M., Morimoto S. Experimental models of inherited
cardiomyopathy and its therapeutics. World J Cardiol. 2014; 6 (12):
1245–51.
12. Becker J.R., Deo R.C., Werdich A.A., et al Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish. Dis Models
Mech. 2011; 4: 400–10. doi:10.1242/dmm.006148.
13. Dzemeshkevich S.L., Frolova Yu.V., Kim S.Yu., et al. Anatomic
and morphological signs of a diffuse – generalized hypertrophic cardiomyopathy. Russ J Cardiol. 2015; Vol. 5 (121): 58–63. (in Russian)
14. McNally E., Dellefave L. Sarcomere mutations in cardiogenesis and ventricular noncompaction. Trends Cardiovasc Med. 2009;
Vol. 19 (1): 17–20.
15. Michael G., Katz M., BrandonWarner E., et al. Mitigation
of myocardial fibrosis by molecular cardiac surgerymediated gene
overexpression. J Thorac Cardiovasc Surg. 2016; Vol. 151 (4).
16. Takayama H., Wendy K., Maurer M., Ginns J., et al. Hypertrophic cardiomyopathy: New approaches and a time to reappraise
older approaches. J Thorac Cardiovasc Surg. 2016; 152 (4): 983–8.
17. Dzemeshkevich S.L. Cardiothoracic transplant and mechanical circulatory support of heart and lang failure (Annal meeting
AATS, Toronto – 2014). Clin Experiment Surg Petrovsky J. 2014; (2):
35–8. (in Russian)
18. Kornberger A., Stock U.A., Risteski P., Beiras A. Fernandez
Left ventricular noncompaction cardiomyopathy and left ventricular assist device: a word of caution. J Cardiothorac Surg. 2016; 11:
108–13.
19. DzemeshkevichS.L.,Yu.V.Frolova,V.V.Raskinetal.Reverse
remodeling of the heart as a method of treatment of patients with
dilated cardiomyopathy. Clin Experiment Surg Petrovsky J. 2014; (1):
29–82. (in Russian)
20. Anyanwu A.C. Superior survival with surgery for early ver-
sus latestage heart disease: Cause and effect or methodologic quirk?
J Thorac Cardiovasc Surg. 2016; 152 (N 2): 401–5.